Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy

International Journal of Hematology

Volumn 104, Issue 2, 2016, Pages 228-235

  Miyakawa, Yoshitaka ^a   Imada, Kazunori ^b,g   Ichinohe, Tatsuo ^c   Nishio, Kenji ^d   Abe, Takayuki ^e   Murata, Mitsuru ^e   Ueda, Yasunori ^f   Fujimura, Yoshihiro ^d   Matsumoto, Masanori ^d   Okamoto, Shinichiro ^e  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KOKURA MEMORIAL HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KURASHIKI CENTRAL HOSPITAL   (Japan)

^g OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

ADAMTS13; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC ANALGESIC AGENT; GANCICLOVIR; HYDROCORTISONE; PREDNISOLONE; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BACTEREMIA; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DYSPNEA; ENZYME ACTIVITY; FEMALE; HERPETIC STOMATITIS; HUMAN; IMMUNOTHERAPY; INFUSION RELATED REACTION; JAPANESE (PEOPLE); LIMIT OF DETECTION; MALE; MULTICENTER STUDY; NOCARDIOSIS; OPEN STUDY; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PLASMAPHERESIS; PROPHYLAXIS; REFRACTORY THROMBOCYTOPENIA; REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA; SEPTIC SHOCK; SPASTICITY; STEROID THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRICHOMONIASIS; URTICARIA; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; METABOLISM; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENT DISEASE; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADAMTS13 PROTEIN; ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RITUXIMAB; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84969242574     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-2019-x     Document Type: Article

References (22)

1. Török TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968–1991. Am J Hematol. 1995;50:84–90.
2. Ministry of Health, Labour and Welfare. Patient survey by injury and disease. 2013. http://www.mhlw.go.jp/toukei/saikin/hw/kanja/10syoubyo/. Accessed 18 Jan 2016 (Internet).
3. Matsumoto M, Bennett CL, Isonishi A, Qureshi Z, Hori Y, Hayakawa M, et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One. 2012;7:e33029.
4. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–94.
5. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1584–94.
6. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010;95:1555–62.
7. Shimizu M, Nomura S, Ishii K, Mohri Y, Umei N, Fujiyama Y, et al. The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis. Thromb Haemost. 2009;101:599–600.
8. Tsai M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010;91:1–19.
9. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–35.
10. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746–53.
11. Clark WF, Rock G, Barth D, Arnold DM, Webert KE, Yenson PR, et al. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. Br J Haematol. 2015;170:208–17.
12. Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis. 2012;34:347–59.
13. Soucemarianadin M, Benhamou Y, Delmas Y, Pichereau C, Maury E, Pène F, et al. Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Eur J Haematol. 2015. doi:10.1111/ejh.12706.
14. Omri HE, Taha RY, Gamil A, Ibrahim F, Sabah HA, Mahmoud ZO, et al. Efficacy and safety of rituximab for refractory and relapsing thrombotic thrombocytopenic purpura: a cohort of 10 cases. Clin Med Insights Blood Disord. 2015;8:1–7.
15. Lim W, Vesely SK, Geoge JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125:1526–31.
16. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444–52.
17. Yagi H, Ito S, Kato S, Hiura H, Matsumoto M, Fujimura Y. Plasma levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity levels. Int J Hematol. 2007;85:403–7.
18. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451–61.
19. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–11.
20. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932–7.
21. Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizuka H, Kuyama J, et al. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol. 2005;81:433–6.
22. Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol. 2004;77:171–6.